Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in CRVO and in Phase 2 Study in DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with m...

Full Story →